Article
KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Lung cancer (Amsterdam, Netherlands) - 1 Feb 2014
Maus M K H, Grimminger P P, Mack P C, Astrow S H, Stephens C, Zeger G, Hsiang J, Brabender J, Friedrich M, Alakus H, Hölscher A H, Lara P, Danenberg K D, Lenz H J, Gandara D R
Abstract excerpt
BACKGROUND: KRAS mutations are associated with diverse biologic functions as well as prognostic and predictive impact in non-small cell-lung cancer (NSCLC) and colorectal cancer (CRC). In CRC, benefit from monoclonal antibody therapies targeting EGFR is generally limited to patients whose tumors have wild-type (WT) KRAS, whereas data suggest that this association is not present for NSCLC. We hypothesized that the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.